Zealand Pharma welcomes Jutta af Rosenborg and Jørgen Lindegaard as new board members

4/28/2011 10:30 AM EST

Zealand Pharma A/S
Company Announcement

Zealand Pharma welcomes Jutta af Rosenborg and Jørgen Lindegaard as new board
members

Copenhagen, 2011-04-28 16:30 CEST (GLOBE NEWSWIRE) -- Company Announcement

No. 07/2011

                                        

                                        

  Zealand Pharma welcomes Jutta af Rosenborg and Jørgen Lindegaard as new board
                                    members





Copenhagen, 28 April 2011 - Zealand Pharma announced that Jutta af Rosenborg
and Jørgen Lindegaard have been elected as new members to the company's Board
of Directors at the Annual General Meeting held today. Christian Herskind
Jørgensen will be leaving the Board. 



At a board meeting following the Annual General Meeting, the new Board
constituted itself with the re-election of Daan Ellens as Chairman and the
election of Jørgen Lindegaard as Vice-Chairman. 



Commenting on today's announcement, Daan Ellens, Chairman of Zealand Pharma,
said: “We are delighted to welcome Jutta and Jørgen to the Board of Zealand
Pharma. They both bring significant experience and competence in the management
of public Danish companies, thereby complementing the existing competences of
the company's management very well. The addition of Jutta and Jørgen as new
board members is a natural and important step for Zealand Pharma as it
completes the transition from a private to a publicly listed company, and I am
convinced they will make valuable contributions to the future development of
the company. On a similar note, we sincerely thank Christian for his
considerable contribution to the evolution of Zealand Pharma to date.” 



Commenting on today's announcement, David Solomon, President and Chief
Executive Officer of Zealand Pharma, said: “I am extremely pleased that Jutta
and Jørgen have agreed to join the Board of Zealand Pharma. The company has
made significant progress in the past year and with a near-term product
opportunity in lixisenatide as a new treatment for Type 2 diabetes, the company
is entering a new phase with a more commercial profile to which both Jutta and
Jørgen can contribute significantly. I look forward to working closely with the
Board to ensure the continued success of Zealand Pharma.” 





Jørgen Lindegaard

Jørgen Lindegaard is currently a member of the board of directors of ISS Group,
Trifina Holding ApS, Trifina Mellemholding ApS and Efsen Engineering A/S. He is
Chairman of the Board of Scania of Denmark A/S, AVT Business School A/S,
Deducta A/S and K/S Vimmelskaftet 39-41 and Deputy Chairman of the Board of the
IT University of Copenhagen. Most recently, Jørgen Lindegaard was Group CEO of
the ISS Group from August 2006 to March 2010. He also served as the CEO of SAS
AB from May 2001 to May 2006 and previously served as the CEO for GN Store Nord
A/S. Jørgen Lindegaard holds a Civil Engineering degree from the Technical
University of Denmark. 









Jutta af Rosenborg

Jutta af Rosenborg is a member of the board and Chairman of the audit committee
of Auriga Industries A/S and has been a member of the board of the investment
fund Carnegie WorldWide since 2006. From 2003 to 2010, Jutta af Rosenborg was
CFO, Executive Vice President for Finance & IT, and member of the Board of
Management of the ALK-Abelló A/S group. Jutta af Rosenborg has previously
filled managerial positions at e.g. Deloitte's auditing and consultancy
department, before she was appointed Vice President Group Accounting at Chr.
Hansen Holding A/S in 2000. Jutta af Rosenborg qualified as a state-authorised
public accountant in 1992 and earned an MSc in Business Administration and
Auditing from Copenhagen Business School in 1987. 





For further information, please contact:

Zealand Pharma

David Solomon, President and Chief Executive Officer

Tel: +45 4328 1200

Hanne Leth Hillman, Vice President, Head of IR and Corporate Communications
Tel: +45 8877 3689
Mobile: +45 5060 3689

M:Communications

Mary-Jane Elliott / Emma Thompson / Amber Bielecka / Ulf Martensson

Tel: +44 20 7920 2330 / +46 8 407 22 43







About Zealand Pharma

Zealand Pharma A/S is a public (NASDAQ OMX: ZEAL) Scandinavian based
biopharmaceutical company with a mature and growing clinical pipeline of
innovative peptide drugs. The company's lead product candidate is a once-daily
GLP-1 in late-stage Phase III development for the treatment of Type 2 Diabetes
in collaboration with sanofi-aventis. Zealand Pharma also has several other
collaboration and licensing partnerships, including a license agreement with
Helsinn Healthcare on a clinical stage GLP-2 drug for the treatment of
Chemotherapy and Radiotherapy Induced Diarrhoea. 

Zealand Pharma has unique expertise in peptide discovery and optimization and
in the development of novel peptide drugs with favourable therapeutic
attributes. The company targets metabolic (diabetes and obesity),
gastrointestinal and cardiovascular diseases, where existing treatments fail to
adequately serve patient needs and where the market potential for improved
treatments through the use of peptide drugs is high. All of Zealand Pharma's
product candidates have been identified through the company's own drug
discovery activities. The company is headquartered in Copenhagen and has
approximately 90 employees. For more information please visit
www.zealandpharma.com.